Invitrogen™ Prasinezumab Recombinant Monoclonal Antibody

Beschreibung

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Prasinezumab (PRX002/RG7935) is an investigational monoclonal antibody that targets alpha-synuclein, a protein that is believed to misfold and aggregate to form the protein structures that are highly implicated in Parkinson's disease pathology. Prasinezumab targets alpha-synuclein and is being developed through a worldwide collaboration with Roche as a potentially disease modifying therapy that is designed to slow or reduce the neurodegeneration associated with alpha-synuclein misfolding and/or its transmission.